ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0056

COVID-19 Among Hospitalized Patients with Kidney Disease: Experience at a Midwestern Medical Center

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Lentine, Krista L., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Pahlavani, Seyedmahdi, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Caliskan, Yasar, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Schnell, Ariel A., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Marino, Nikolas Evan, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Taylor, Aberdeen X., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Elewa, Usama, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Philipneri, Marie D., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Mosman, Amy, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Vo, Thanh-Mai Nguyen, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Ouseph, Rosemary, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Ainapurapu, Sruthi, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Groll, Thomas Richard, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
Background

Manifestations of novel coronavirus disease-2019 (COVID-19) range from minimal symptoms to organ failure and death. Preliminary studies suggest that acute kidney injury (AKI) is a common complication of COVID-19 and may predict adverse outcomes. Patients with chronic kidney diseases may be vulnerable to increased risk of serious COVID-19-related complications.

Methods

In this (ongoing) retrospective cohort study, we examined the characteristics, presentations, treatments, and outcomes of COVID-19 among hospitalized patients with AKI, dialysis-dependent end-stage kidney disease (ESKD-D) or kidney transplantation (KTx) at an urban, Midwestern tertiary center (3/19/2021–3/25/2021).

Results

Among 184 patients, 91 had AKI (49%), 51 CKD5-D (28%), and 42 patients were KTx recipients (23%). Monthly cases ranged from 6 in March to 35 patients in December 2020. Among the cohort, 61% were Black (including 50% AKI, 82% ESKD-D, and 57% KTx). Overall, 35% required mechanical ventilation, with highest use in the AKI group (51%). 48% of AKI patients required renal replacement therapy (RRT) and 9% treated with ECMO. Mechanical ventilation was lower among KTx recipients (12%) and 9% required RRT. The most common medical treatment was dexamethasone (48%). Mortality was 46% in the AKI and 23% in CKD5-D groups, but 2% among KTx recipients.

Conclusion

We observed high mortality associated with COVID-19 among hospitalized patients with kidney disease, especially in those with AKI. Public health and therapeutic studies should focus on mitigating COVID-19 disease transmission and optimizing outcomes in this vulnerable population.

Cohort Characteristics and Key Outcomes